Related Experiment Video
Updated: Jul 13, 2025
Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
Published on: December 20, 2024
Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future
William Echavidre1, Daniel Fagret2, Marc Faraggi3
1Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco.
Abstract:
The theranostic approach in oncology holds significant importance in personalized medicine and stands as an exciting field of molecular medicine. Significant achievements have been made in this field in recent decades, particularly in treating neuroendocrine tumors using 177-Lu-radiolabeled somatostatin analogs and, more recently, in addressing prostate cancer through prostate-specific-membrane-antigen targeted radionuclide therapy. The promising clinical results obtained in these indications paved the way for the further development of this approach. With the continuous discovery of new molecular players in tumorigenesis, the development of novel radiopharmaceuticals, and the potential combination of theranostics agents with immunotherapy, nuclear medicine is poised for significant advancements. The strategy of theranostics in oncology can be categorized into (1) repurposing nuclear medicine agents for other indications, (2) improving existing radiopharmaceuticals, and (3) developing new theranostics agents for tumor-specific antigens. In this review, we provide an overview of theranostic development and shed light on its potential integration into combined treatment strategies.
Insights
Theranostics in oncology, combining targeted therapies and diagnostics, offers personalized medicine advancements. This approach shows promise in treating neuroendocrine tumors and prostate cancer, with future potential in immunotherapy combinations.
Area of Science:
- Molecular medicine
- Oncology
- Nuclear medicine
Background:
- Theranostics is crucial for personalized cancer medicine.
- Recent successes include 177-Lu-somatostatin analogs for neuroendocrine tumors and PSMA-targeted therapy for prostate cancer.
Purpose of the Study:
- To review the development of theranostic approaches in oncology.
- To explore the integration of theranostics with combined treatment strategies.
Main Methods:
- Review of current theranostic strategies in oncology.
- Categorization of theranostic approaches: repurposing, improvement, and novel agent development.
Main Results:
- Significant clinical achievements in treating specific cancers using theranostics.
- Identification of key areas for future development in radiopharmaceuticals and molecular targets.
Conclusions:
- Theranostics is a rapidly advancing field in nuclear medicine.
- Potential for significant impact through novel radiopharmaceuticals, target discovery, and combination therapies like immunotherapy.
Related Concept Videos
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
03:20Nuclear Transmutation
01:25Applications Of NMR In Biology